Wednesday, July 8, 2026

pharma · Advanced Solid Tumor · Sarcoma · PRLD

Prelude Therapeutics

Prelude Therapeutics is a pharma organization headquartered in Wilmington, USA. It trades on NYSE under ticker PRLD. Primary therapeutic focus areas include Advanced Solid Tumor, Sarcoma, Acute Myeloid Leukemia, Polycyth

175 Innovation Boulevard, Wilmington, DE 19805, US HQ
2016 Founded
111 Employees
Public company Type
PRLD · NYSE Ticker
Company details
Status
Public
HQ
175 Innovation Boulevard, Wilmington, DE 19805, US
Founded
2016
Employees
111
Programs
13
Drugs
5
Patents
16
Clinical program

PRT1419

Phase 1 · small molecule · Multiple Myeloma

PRT1419 for Multiple Myeloma is a Phase 1 program (small_molecule) at Prelude Therapeutics Inc with 1 ClinicalTrials.gov record(s).

← All Prelude Therapeutics Inc projects Phase 1 small molecule completed

Internal code PRT1419-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Prelude Therapeutics Inc
Phase
Phase 1
Modality
small_molecule
Indication
Multiple Myeloma
Status
completed
Trials
1

Clinical trials